Corinne Nevinny

Corinne grew up in Newton Center, Massachusetts and Lake Forest, Illinois before attending Stanford. An industrial engineering major, Corinne still found the time to play varsity tennis and was part of the National Championship-winning team her freshman year. After earning her MBA at HBS, Corinne worked as an investment banker specializing in health care, first in New York and then returning to California. She worked at a number of firms including Kidder Peabody, Dillon Read and UBS.

Catching the itch to join an operating company, Corinne became CFO of biotech company Tularik where she led the company’s IPO. Corinne then joined Edwards Lifesciences as CFO and subsequently assumed the role of President of Global Operations and GM of the CardioVascular Division.

Corinne has served as a board member and chair of the audit committee of three publicly traded therapeutics companies: Onyx Pharmaceuticals (sold to Amgen); Avanir (sold to Otsuka); and Neurocrine Biosciences. Corinne currently serves on as the chair of the audit committee of Insulet Corporation, is on both the Board and the Executive Committee of the US Olympic and Paralympic Foundation, and is a member of the Black Economic Alliance.

Of her many achievements, Corinne’s proudest accomplishment has been raising her two sons, William and Konrad.

In 2019, she and Harvard Business School friend Linda Greub launched Avestria Ventures.